DBV Technologies SA - American (DBVT) AI Stock Analysis

• Market Cap: $247.02M
• Dividend Yield: N/A
• Average Volume (3M): 50.52K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.01
• Revenue Growth: N/A
• EPS Growth: -38.74%
• Country: US
• Employees: 106
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -0.26
• Shares Outstanding: 27,389,774
• 10 Day Avg. Volume: 26,791
• 30 Day Avg. Volume: 50,521
• PEG Ratio: 0.41
• Price to Book (P/B): 6.09
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -20.97
• Enterprise Value/Market Cap: 7.26
• Enterprise Value/Revenue: 61.78
• Enterprise Value/Gross Profit: -431.33
• Enterprise Value/Ebitda: -4.51
• 1Y Price Target: $15.81
• Price Target Upside: 78.04% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 51 Neutral
• Price Target: $9.50 ▲(6.98%Upside)

DBV Technologies' overall score is primarily driven by financial challenges, including declining revenues and liquidity issues. However, positive corporate events, such as significant financing and product advancement, provide a counterbalance, reflecting potential for future growth. The technical outlook is moderate, and valuation concerns persist due to negative earnings.

Positive Factors

Clinical Trials

Viaskin Peanut's efficacy and safety continue to improve over time in 1-3 year olds, with new analysis supporting its proposed labeling approach.

Market Opportunity

Given the regulatory clarity, investors now have the goal line for Viaskin Peanut in sight, which is relatively derisked, and can start evaluating the commercial opportunity which could be ~$2B+ annually.

Regulatory Approvals

The FDA confirms requirements for Viaskin Peanut’s accelerated approval pathway in toddlers with DBV Technologies targeting BLA submissions in toddlers and children.

Negative Factors

Clinical Trial Risks

The VITESSE trial in peanut-allergic children (4–7 years) represents the last major clinical risk for Viaskin, with the Phase 3 trial fully enrolled and using a modified patch informed by previous studies.

Financial Position

DBVT ended the year with $33M in cash which management said is sufficient to fund operations into April, so management will need to bring in capital immediately.

DBV Technologies SA - American Business Overview & Revenue Model

Company Description

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

How the Company Makes Money

DBV Technologies makes money by developing and potentially commercializing its pipeline of products based on the Viaskin platform. The company's revenue model is centered around the successful development, approval, and eventual commercialization of its lead product, Viaskin Peanut, as well as other potential products in its pipeline. DBV Technologies may also generate revenue through strategic partnerships, research and development collaborations, and licensing agreements with other pharmaceutical companies. These partnerships could potentially provide upfront payments, milestone payments, and royalties on product sales, contributing to the company's earnings.

DBV Technologies SA - American Financial Statement Overview

Summary

DBV Technologies SA is facing significant financial challenges with declining revenues and ongoing losses. While the low debt-to-equity ratio is a positive, negative cash flow and net profit margin indicate financial instability.

Income Statement

DBV Technologies SA has experienced a significant decline in revenue from $15.73 million in the previous year to $2.57 million in the TTM (Trailing-Twelve-Months), indicating a revenue contraction. The company also posted negative EBIT and net income margins, reflecting ongoing operational challenges and high expenses relative to revenue. Despite gross profit being positive, the net profit margin remains negative.

Balance Sheet

The company maintains a relatively low debt-to-equity ratio, indicating limited leverage which is a positive aspect. However, the return on equity is negative due to the net losses, and the equity ratio has declined, indicating reduced financial stability. This suggests potential challenges in maintaining equity levels without external financing.

Cash Flow

DBV Technologies SA reported a negative free cash flow, with a deterioration in operating cash flow compared to the previous year. The free cash flow to net income ratio is negative, indicating cash flow issues. Despite a slight improvement in financing cash flow, the overall cash flow situation points to liquidity challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.16M	2.57M	15.73M	4.80M	5.71M	11.28M
Gross Profit	-4.16M	-4.26M	15.73M	-15.50M	-3.56M	-17.49M
EBITDA	-107.89M	-111.18M	-67.37M	-76.68M	-87.24M	-99.25M
Net Income	-113.65M	-113.92M	-72.73M	-96.30M	-97.81M	-195.68M
Balance Sheet
Total Assets	50.56M	65.66M	182.99M	246.50M	146.72M	333.87M
Cash, Cash Equivalents and Short-Term Investments	12.96M	32.46M	141.37M	209.20M	77.30M	240.80M
Total Debt	0.00	7.80M	6.55M	10.02M	18.69M	40.63M
Total Liabilities	47.69M	38.27M	42.80M	52.00M	47.45M	81.87M
Stockholders Equity	2.87M	27.39M	140.19M	194.50M	99.27M	252.01M
Cash Flow
Free Cash Flow	-90.46M	-106.81M	-80.33M	-56.45M	-109.16M	-206.48M
Operating Cash Flow	-89.45M	-104.47M	-79.65M	-55.70M	-108.24M	-203.10M
Investing Cash Flow	1.00M	-757.00K	-808.00K	-100.00K	-433.00K	―
Financing Cash Flow	694.00K	587.00K	6.77M	194.10M	274.00K	183.40M

DBV Technologies SA - American Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.88
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DBVT, the sentiment is Positive. The current price of 8.88 is above the 20-day moving average (MA) of 8.86, below the 50-day MA of 9.19, and above the 200-day MA of 5.39, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 48.87 is Neutral, neither overbought nor oversold. The STOCH value of 25.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DBVT.

DBV Technologies SA - American Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PLX	56 Neutral	$122.59M	36.67	10.42%	―	0.18%	-55.15%
CDTX	56 Neutral	$1.03B	―	-299.58%	―	-99.35%	-260.33%
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.33%	16.99%	1.69%
DBVT	51 Neutral	$247.02M	―	-198.47%	―	―	-38.74%
ENGN	42 Neutral	$187.05M	―	-33.97%	―	―	―
CRVS	41 Neutral	$299.98M	―	-100.13%	―	―	-71.53%
CRGX	40 Underperform	$193.21M	―	-65.94%	―	―	―

DBV Technologies SA - American Corporate Events

DBV Technologies Launches COMFORT Toddlers Safety Study

On June 25, 2025, DBV Technologies announced the screening of the first subject in their COMFORT Toddlers supplemental safety study, which targets peanut-allergic toddlers aged 1 to 3 years. The study, involving approximately 480 subjects across multiple countries, aims to supplement safety and efficacy data for the Viaskin Peanut patch. This development marks a significant step towards potentially advancing the Viaskin Peanut patch to market, with data supporting a Biologics License Application submission anticipated in the second half of 2026 under the FDA’s Accelerated Approval Pathway. The initiation of this study underscores DBV Technologies’ commitment to addressing the unmet needs of food allergic patients.

The most recent analyst rating on (DBVT) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on DBV Technologies SA – American stock, see the DBVT Stock Forecast page.

DBV Technologies SA Approves Key Governance Amendments

On June 11, 2025, DBV Technologies SA held its Annual General Meeting where shareholders approved several resolutions, including the 2024 ex-post compensation for CEO Daniel Tassé and exceptional bonuses for other executives. Additionally, the meeting resulted in amendments to the company’s bylaws, allowing the Board of Directors to make decisions through written consultation and setting an age limit for the Chairman at 80 years. These changes reflect the company’s ongoing efforts to refine its governance structure and executive compensation policies, potentially impacting its operational efficiency and stakeholder relations.

The most recent analyst rating on (DBVT) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on DBV Technologies SA – American stock, see the DBVT Stock Forecast page.

DBV Technologies Secures $306.9M for Viaskin Peanut Program

On March 27, 2025, DBV Technologies announced a private placement agreement to raise up to $306.9 million (€284.5 million) to advance its Viaskin Peanut program. The financing, led by prominent healthcare investors, will support the company’s efforts to submit a Biologics License Application to the FDA and prepare for a potential U.S. launch. The funding will result in a dilution of existing shareholders but reflects strong investor confidence in the Viaskin Peanut patch’s potential impact on treating pediatric peanut allergies.